refractory B-cell precursor acute lymphoblastic leukemia (DBCOND0093790)

Identifiers

Synonyms

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory / Precursor B-lymphoblastic lymphoma/leukemia refractory / Refractory B cell precursor Acute lymphoblastic leukemia / Refractory B-cell precursor Acute Lymphoblastic Anemia / Precursor B-lymphoblastic lymphoma refractory / Precursor B-lymphoblastic lymphoma NOS refractory

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Blinatumomab	An antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD).	B-lymphocyte antigen CD19target T-cell surface glycoprotein CD3 delta chaintarget
Brexucabtagene autoleucel	A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ζ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma.	B-lymphocyte antigen CD19target
Tisagenlecleucel	A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.	B-lymphocyte antigen CD19target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03321123	MB-CART19.1 in Patients With R/R ALL	Tisagenlecleucel	treatment	2	unknown_status